Cara Therapeutics, Inc. (CARA), a commercial-stage biopharmaceutical company focused on pruritus, announced Monday the Approval of KORSUVA IV Injection Syringe in Japan to treat pruritus in hemodialysis patients. The company now would receive $1.5 million milestone payment from its licensing partner Maruishi Pharmaceutical Co., Ltd under the deal.
from RTT - Before the Bell https://ift.tt/UM0i5Iw
via IFTTT
No comments:
Post a Comment